CBB1007 (trihydrochloride)
CBB1007 trihydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma[1][2].
Product Specifications
CAS Number
2070015-03-9
UNSPSC
12352005
Target
Histone Demethylase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/CBB1007-trihydrochloride.html
Purity
97.08
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
NC(N1CCN(CC1)CC2=CC(C(OC)=O)=CC(C(N3CCN(CC3)C(C4=CC=C(C=C4)C(N)=N)=O)=O)=C2)=N.[H]Cl.[H]Cl.[H]Cl
Molecular Formula
C27H37Cl3N8O4
Molecular Weight
643.99
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
KDM1/LSD1
Citation 01
Clin Exp Med. 2025 Nov 25;26 (1) :33.|BMC Neurosci. 2022 Nov 10;23 (1) :63.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD99 / MIC2 (Ewing's Sarcoma Marker), Biotin conjugate, 0.1mg/mL
